Literature DB >> 18458726

Prediction of response within the first 3 days to treatment with paroxetine for depression.

Takuji Inagaki1, Motohide Furuya, Tetsuya Kawamukai, Shihoh Okazaki, Hideaki Yasuda, Maiko Hayashida, Tsuyoshi Miyaoka, Akira Nishida, Jun Horiguchi.   

Abstract

OBJECTIVE: In the treatment of depression, clinical and psychopharmacologic aspects have been investigated to predict the response to anti-depressants. Some trials have reported clinical improvement as early as the first week; however, few have investigated the early effects of selective serotonin reuptake inhibitors. The aim of this study was to investigate therapeutic efficacy of paroxetine within the first 3 days of therapy onset.
METHOD: Subjects included 29 outpatients diagnosed at first interview with major depressive disorder according to DSM-IV criteria (June 2003 to January 2007). Paroxetine 5-20 mg/day was administered for at least 2 weeks. Treatment efficacy was defined as a > 50% decrease in Hamilton Rating Scale for Depression (HAM-D) total scores from baseline to the end of the second week. To determine efficacy within the first 3 days, patients completed the HAM-D as a self-rated questionnaire on the first and third days and at the end of the first, second, and fourth weeks. RESULT: Subjects were divided into 2 groups: successful (17 responders) and failed (12 non-responders). There was a significant difference between the reduction rates of self-rated HAM-D total scores on the third day (p < .01).
CONCLUSION: In patients responding to paroxetine in the early stages of treatment, the prediction of response within the first 3 days using the self-rated HAM-D is suggested.

Entities:  

Year:  2008        PMID: 18458726      PMCID: PMC2292438          DOI: 10.4088/pcc.v10n0207

Source DB:  PubMed          Journal:  Prim Care Companion J Clin Psychiatry        ISSN: 1523-5998


  10 in total

1.  Treatment of depression and concomitant anxiety.

Authors:  D Nutt
Journal:  Eur Neuropsychopharmacol       Date:  2000-12       Impact factor: 4.600

2.  A rating scale for depression.

Authors:  M HAMILTON
Journal:  J Neurol Neurosurg Psychiatry       Date:  1960-02       Impact factor: 10.154

3.  The relationship of personality disorders to treatment outcome in depressed outpatients.

Authors:  Roger T Mulder; Peter R Joyce; Suzanne E Luty
Journal:  J Clin Psychiatry       Date:  2003-03       Impact factor: 4.384

Review 4.  Early onset of selective serotonin reuptake inhibitor antidepressant action: systematic review and meta-analysis.

Authors:  Matthew J Taylor; Nick Freemantle; John R Geddes; Zubin Bhagwagar
Journal:  Arch Gen Psychiatry       Date:  2006-11

5.  Once-daily duloxetine 60 mg in the treatment of major depressive disorder: multicenter, double-blind, randomized, paroxetine-controlled, non-inferiority trial in China, Korea, Taiwan and Brazil.

Authors:  Phil Lee; Liang Shu; Xiufeng Xu; Chuan Yue Wang; Min Soo Lee; Chia-Yih Liu; Jin Pyo Hong; Sandra Ruschel; Joel Raskin; Samuel A Colman; Gavan A Harrison
Journal:  Psychiatry Clin Neurosci       Date:  2007-06       Impact factor: 5.188

6.  The importance of the first three days: predictors of treatment outcome in depressed in-patients.

Authors:  S Priebe; T Gruyters
Journal:  Br J Clin Psychol       Date:  1995-05

7.  Early subjective reactions predicting the outcome of hospital treatment in depressive patients.

Authors:  S Priebe
Journal:  Acta Psychiatr Scand       Date:  1987-08       Impact factor: 6.392

8.  Prediction of efficacy of antidepressant by 1-week test therapy in depression.

Authors:  H Nagayama; K Nagano; A Ikezaki; T Tashiro
Journal:  J Affect Disord       Date:  1991-12       Impact factor: 4.839

9.  Onset and early behavioral effects of pharmacologically different antidepressants and placebo in depression.

Authors:  Martin M Katz; Janet L Tekell; Charles L Bowden; Steve Brannan; John P Houston; Nancy Berman; Alan Frazer
Journal:  Neuropsychopharmacology       Date:  2004-03       Impact factor: 7.853

10.  A comparison of paroxetine, imipramine and placebo in depressed out-patients.

Authors:  G C Dunbar; J B Cohn; L F Fabre; J P Feighner; R R Fieve; J Mendels; R K Shrivastava
Journal:  Br J Psychiatry       Date:  1991-09       Impact factor: 9.319

  10 in total
  2 in total

1.  Sex differences in the prediction of the effectiveness of paroxetine for patients with major depressive disorder identified using a receiver operating characteristic curve analysis for early response.

Authors:  Tetsu Tomita; Norio Yasui-Furukori; Yasui-Furukori Norio; Yasushi Sato; Taku Nakagami; Shoko Tsuchimine; Ayako Kaneda; Sunao Kaneko
Journal:  Neuropsychiatr Dis Treat       Date:  2014-04-08       Impact factor: 2.570

2.  Does G2677T Polymorphism of the MDR1 Gene Make a Difference in the Therapeutic Response to Paroxetine in Depressed Patients in a Slovakian Population?

Authors:  Zuzana Vancova; Martina Cizmarikova; Jozef Dragasek; Silvia Zofcakova; Peter Kolarcik; Jan Mojzis
Journal:  Med Sci Monit       Date:  2018-05-13
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.